Homocysteine levels in patients with coronary slow flow phenomenon: A meta-analysis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 15 02 2023
accepted: 18 06 2023
medline: 10 7 2023
pubmed: 7 7 2023
entrez: 7 7 2023
Statut: epublish

Résumé

With the development of coronary angiography, more and more attention has been paid to coronary slow flow phenomenon (CSFP). Recent studies have found that the correlation between homocysteine (Hcy) levels and CSFP was contradictory, so we conducted this meta-analysis to investigate the correlation. By March 2022, studies that meet the research requirements were identified by searching multiple databases including Embase, Web of Science, and PubMed. We included studies evaluating the correlation between Hcy levels and CSFP. Random or fixed effect meta-analyses were performed according to heterogeneity among included studies. A leave-out method and subgroup analyses were conducted to determine the source of heterogeneity. Thirteen studies involving 625 CSFP and 550 subjects were included. After pooling data from each study, Hcy levels were higher in the CSFP groups (standard mean difference [SMD], 1.45; 95% CI, 0.94 to 1.96, P < .00001) than in the control group. In the meta-analysis, there was significant heterogeneity (I2 = 93%), which was further explored through leave-out method and and subgroup analyses. Specifically, pooling data from studies with a mean thrombolysis in myocardial infarction (TIMI) frame count ≥ 46 (SMD, 1.31; 95% CI, 1.00 to 1.63, P < .00001) resulted in no heterogeneity (0%), indicating that the TIMI frame count ≥ 46 was the source of heterogeneity. Our study found that elevated Hcy levels are strongly associated with CSFP. More importantly, the association was stronger in CSFP patients with mean TIMI frame count ≥ 46.

Sections du résumé

BACKGROUND BACKGROUND
With the development of coronary angiography, more and more attention has been paid to coronary slow flow phenomenon (CSFP). Recent studies have found that the correlation between homocysteine (Hcy) levels and CSFP was contradictory, so we conducted this meta-analysis to investigate the correlation.
METHODS METHODS
By March 2022, studies that meet the research requirements were identified by searching multiple databases including Embase, Web of Science, and PubMed. We included studies evaluating the correlation between Hcy levels and CSFP. Random or fixed effect meta-analyses were performed according to heterogeneity among included studies. A leave-out method and subgroup analyses were conducted to determine the source of heterogeneity.
RESULTS RESULTS
Thirteen studies involving 625 CSFP and 550 subjects were included. After pooling data from each study, Hcy levels were higher in the CSFP groups (standard mean difference [SMD], 1.45; 95% CI, 0.94 to 1.96, P < .00001) than in the control group. In the meta-analysis, there was significant heterogeneity (I2 = 93%), which was further explored through leave-out method and and subgroup analyses. Specifically, pooling data from studies with a mean thrombolysis in myocardial infarction (TIMI) frame count ≥ 46 (SMD, 1.31; 95% CI, 1.00 to 1.63, P < .00001) resulted in no heterogeneity (0%), indicating that the TIMI frame count ≥ 46 was the source of heterogeneity.
CONCLUSIONS CONCLUSIONS
Our study found that elevated Hcy levels are strongly associated with CSFP. More importantly, the association was stronger in CSFP patients with mean TIMI frame count ≥ 46.

Identifiants

pubmed: 37418362
doi: 10.1371/journal.pone.0288036
pii: PONE-D-23-03651
pmc: PMC10328313
doi:

Substances chimiques

Homocysteine 0LVT1QZ0BA

Types de publication

Meta-Analysis Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0288036

Informations de copyright

Copyright: © 2023 Yu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Acta Pharmacol Sin. 2021 Oct;42(10):1598-1609
pubmed: 33495519
Circulation. 1996 Mar 1;93(5):879-88
pubmed: 8598078
Eur Urol. 2021 Mar;79(3):325-326
pubmed: 33375994
FASEB J. 2003 Mar;17(3):512-4
pubmed: 12551843
Clin Cardiol. 2008 Aug;31(8):352-5
pubmed: 17957738
Helicobacter. 2007 Aug;12(4):298-305
pubmed: 17669101
Cardiology. 2002;97(4):197-202
pubmed: 12145474
Int J Mol Sci. 2020 Oct 18;21(20):
pubmed: 33080955
Circ J. 2012;76(4):936-42
pubmed: 22293446
Interv Med Appl Sci. 2019 Jun;11(2):89-94
pubmed: 32148911
Biomark Med. 2019 Dec;13(17):1439-1446
pubmed: 31617742
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
J Am Soc Echocardiogr. 2004 Dec;17(12):1281-5
pubmed: 15562267
Exp Ther Med. 2020 Aug;20(2):938-944
pubmed: 32742337
Mol Neurobiol. 2018 Apr;55(4):2952-2958
pubmed: 28456936
Cardiovasc Diagn Ther. 2011 Dec;1(1):37-43
pubmed: 24282683
Int J Cardiol. 2005 Jul 20;102(3):419-23
pubmed: 16004886
Coron Artery Dis. 2014 Dec;25(8):653-7
pubmed: 25036859
Am Heart J. 1972 Jul;84(1):66-71
pubmed: 5080284
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Tunis Med. 2011 Jul;89(7):621-6
pubmed: 21780037
Indian Heart J. 2018 May - Jun;70(3):405-409
pubmed: 29961458
Atherosclerosis. 2009 Jun;204(2):412-7
pubmed: 18996527
Int J Mol Sci. 2021 Feb 19;22(4):
pubmed: 33669577
J Am Coll Cardiol. 2001 May;37(6):1523-8
pubmed: 11345360
Cardiology. 2012;121(3):197-203
pubmed: 22508423
Circulation. 2007 Jan 16;115(2):255-62
pubmed: 17200441
Quant Imaging Med Surg. 2022 May;12(5):2767-2776
pubmed: 35502380
Circulation. 1991 Sep;84(3):1087-99
pubmed: 1884441
Cardiology. 2007;108(3):186-92
pubmed: 17085937
Coron Artery Dis. 2006 May;17(4):331-7
pubmed: 16707955
Cardiovasc Res. 2011 Dec 1;92(3):466-75
pubmed: 21933910
J Korean Med Sci. 2012 Jun;27(6):614-8
pubmed: 22690091
Int J Cardiol. 2005 May 11;101(1):143-5
pubmed: 15860399
Scand J Clin Lab Invest. 2012 Oct;72(6):495-500
pubmed: 22950626
Diagn Pathol. 2014 Sep 26;9:167
pubmed: 25257241
J Cardiovasc Dis Res. 2012 Oct;3(4):276-9
pubmed: 23233770
Med Sci Monit. 2001 Sep-Oct;7(5):1029-33
pubmed: 11535954
J Evid Based Med. 2021 Sep;14(3):208-217
pubmed: 33145936

Auteurs

Hong Yu (H)

Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
School of Life Sciences, Westlake University, Hangzhou, 310024, China.

Bei-Bei Wang (BB)

Department of Cardiology, The First People's Hospital of Jinzhong, Jinzhong, 030699, China.

Meng Zhao (M)

Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, 310024, China.

Feng Feng (F)

Institute of Physical Education, Inner Mongolia Normal University, Hohhot, 010000, China.

Hua-Dong Li (HD)

Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,430022, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH